Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling
Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this study, we investigated the therapeutic effect of miR-155 inhibit...
Saved in:
Main Authors: | Shashi Bala (Author), Yuan Zhuang (Author), Prashanth Thevkar Nagesh (Author), Donna Catalano (Author), Adam Zivny (Author), Yanbo Wang (Author), Jun Xie (Author), Guangping Gao (Author), Gyongyi Szabo (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice
by: Fatemeh Momen-Heravi, et al.
Published: (2021) -
The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis
by: Zhibin Yan, et al.
Published: (2021) -
miR-155 in the Resolution of Atherosclerosis
by: Robyn Bruen, et al.
Published: (2019) -
Preparation of a miR-155-activating nucleic acid nanoflower to study the molecular mechanism of miR-155 in inflammation
by: Wenxin Wang, et al.
Published: (2022) -
miR-155 Regulated Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis
by: Jinshan Ye, et al.
Published: (2016)